Determination of the prescription dose for biradionuclide permanent prostate brachytherapy

Vincent Nuttens, Stéphane Lucas

Research output: Contribution to journalArticlepeer-review

Abstract

A model based on the linear quadratic model that has been corrected for repopulation, sublethal cell damage repair, and RBE effect has been used to determine the prescription dose for prostate permanent brachytherapy using seeds loaded with a mixture of Pd103 and I125 or a mixture of Pd103 and Cs131. The prescription dose was determined by comparing the tumor cell survival fractions between the considered biradionuclide seed implant and one monoradionuclide seed implant chosen from Pd103, I125, and Cs131. Prostate edema is included in the model. The influence of the value of the radiobiological parameters and RBE were also investigated. Two mixtures of radionuclides were considered: Pd0.75103 - I0.25125 and Pd0.25103 - Cs0.75131, where the subscripts indicate the fractions of total initial internal activity in the biradionuclide seed. These fractions were selected in order to obtain a dose distribution that lies between that of Pd103 and I125 Cs131. As expected, the computed prescription dose values are dependent on the model parameters (edema half-life and magnitude, radiobiogical parameters, and RBE). The radionuclide used as a benchmark also has a strong impact on the derived prescribed dose. The large uncertainties in the radiobiological parameters and RBE values produce big errors in the computed prescribed dose. Averaged over the range of all the parameters and depending on the radionuclide used as a benchmark (in subscript), the derived prescription dose for the first mixture (PdI) would be: DPd PdI = 142 -16 +15 Gy and DI PdI = 142 -8 +6 Gy; and DPd PdCs = 128 -13 +13 Gy and DCs PdCs = 115 -7 +6 Gy for the PdCs mixture. The uncertainties could be reduced if the radiobiological parameters and RBE value were known more accurately. However, as edema characteristics are patient dependent and can be obtained only after the treatment, an unpredictable error is unavoidable. © 2008 American Association of Physicists in Medicine.
Original languageEnglish
Pages (from-to)5451-5462
Number of pages12
JournalMedical physics
Volume35
Issue number12
DOIs
Publication statusPublished - 1 Jan 2008

Keywords

  • biological effects of ionising radiation
  • cancer
  • dosimetry
  • biological organs
  • brachytherapy
  • tumours
  • cellular effects of radiation

Fingerprint Dive into the research topics of 'Determination of the prescription dose for biradionuclide permanent prostate brachytherapy'. Together they form a unique fingerprint.

Cite this